DOI:
10.1039/D5SC04881H
(Edge Article)
Chem. Sci., 2025, Advance Article
Coordination sphere interactions drive isomer selection in heteroleptic Pd(II) cages with low-symmetry ligands
Received
2nd July 2025
, Accepted 22nd August 2025
First published on 8th September 2025
Abstract
The targeted formation of low-symmetry coordination cages represents a significant design challenge but offers the potential to engineer bespoke molecular hosts with precision. In this work, we have combined the design principles of geometric complementarity and coordination sphere engineering to direct the site- and orientation-selective self-assembly of heteroleptic Pd2LA2LB2-type coordination cages from low-symmetry ligands. The effects of different combinations of heterocyclic donors and their locations within the cage structures on isomer distributions were studied, providing insights on shifts in the balance between non-covalent interactions in the first and second coordination spheres of the cages. For cages with one low-symmetry ligand, switching between selective formation of syn- (up to 77%) or anti-isomers (up to 76%) was achieved simply through minor structural changes (swapping a hydrogen atom for a fluorine) or changing the location of heterocycles within the cage structure between the different ligand scaffolds. Furthermore, the selective (up to ∼62%) assembly of particular isomers of heteroleptic cages formed from two low-symmetry ligand scaffolds was demonstrated and rationalised.
Introduction
Coordination cages are discrete, three-dimensional, metal–organic assemblies with appreciable internal cavities capable of binding guest species.1 Host–guest chemistry within these confined spaces has been exploited for binding anions,2 pollutants,3 drugs4 and gases,5 and for use in catalysis,6 stabilisation of reactive species7 and molecular separations.8
Most commonly, coordination cages are assembled from single, high-symmetry ligands, generally resulting in highly symmetrical architectures. More structurally sophisticated, low-symmetry cages, however, have the potential to exhibit bespoke properties and behaviours.9 As such, there has been interest in developing strategies for the site-selective assembly of heteroleptic (mixed-ligand) cages10 (Fig. 1a), and the orientation-selective assembly of cages from low-symmetry ligands11 (Fig. 1b). In both instances, without sufficient driving force, statistical mixtures of isomers (and other assemblies) can form. Very recently, solutions to the challenge of incorporating low-symmetry ligands into heteroleptic cages (Fig. 1c) have also begun to be investigated.12
 |
| Fig. 1 Approaches to reduced symmetry coordination cages include (a) heteroleptic cages with combinations of ligands, (b) homoleptic cages assembled from low-symmetry ligands, and (c) heteroleptic cages assembled from (i) one or (ii) two low-symmetry ligands in which isomer selectivity can be tuned through structural design (this work). | |
Geometric complementarity between ligands has been used to drive the formation of heteroleptic structures,13 and similar design ideas have enabled the orientation-selective assembly of low-symmetry ligands.14 Coordination sphere engineering – using non-covalent interactions, such as steric bulk or hydrogen bonding (HB), to direct the coordination environment around metal ions15 – is another strategy that has been successfully employed within both heteroleptic16 and low-symmetry ligand systems.17
We recently investigated the self-assembly of homoleptic PdnL2n assemblies from low-symmetry ligands that incorporated either quinoline or picoline donors in combination with unsubstituted pyridines.18 Molecular modelling demonstrated that arranging the bulky quinoline/picoline donors trans to each other would give the lowest energy assemblies. Although experimentally this held true for ligands with picoline donors, quinolines unexpectedly favoured formation of cis-PdnL2n species. This difference in isomer selectivity was shown to be due to HB interactions between acidic protons of the coordinating donor units and solvent molecules. Such intermolecular non-covalent interactions within the second coordination spheres of the Pd(II) ions of the cages could therefore override primary structural factors (i.e. steric bulk) in dictating self-assembly outcomes.
Within this previous work we reported a preliminary investigation of the heteroleptic cage Pd21AB22AA2 (see below) which, due to the unsymmetrical structure of ligand 1AB, could exist as syn- and anti-isomers (Fig. 2). Chemical intuition, combined with molecular modelling, suggested the anti-isomer, with bulky quinoline groups situated far apart, would be lower in energy. The experimentally observed predominant formation of the more sterically encumbered syn-isomer, however, again suggested stabilising interactions in the second coordination sphere of the cage were superseding repulsive steric interactions in the first coordination sphere.
 |
| Fig. 2 Self-assembly of low-symmetry ligands 1 and ligands 2/3/4 with Pd(II) ions forms syn- and anti-isomers, the latter of which are calculated (GFN2-xTB) to be lower in energy. | |
Stemming from this initial result, we were motivated to investigate a wider range of heteroleptic structures to observe the impact on isomer selectivity. In this regard, we wished to explore how isomer selectivity was influenced by (i) the identity of the symmetrical ligand; (ii) the combination of different heterocyclic donors on the unsymmetrical ligand, and (iii) the relative locations of the different donors within the cages. Finally, we also sought to achieve (iv) the selective formation of particular isomers of Pd2LA2LB2 cages assembled from two low-symmetry ligands. Gaining insights into how the, often subtle, balance of interactions that drive self-assembly outcomes can be shifted through design of structure and function will aid in the future development of structurally sophisticated metal–organic assemblies.
Results and discussion
System design and nomenclature
In this work we explored ligand scaffolds 1 and 2 (Fig. 2) that have previously been shown by Severin to be geometrically matched and able to undergo integrative self-assembly with Pd(II) ions to form cis-[Pd21222]4+ heteroleptic cages.19 Ligands 3 and 4 are isostructural to 2 except that the core benzene unit is replaced with a pyridine and toluene, respectively. Each ligand has two N-heterocyclic donors. A two letter combination is used within each ligand name to signify which heterocycles are incorporated into the ligand: pyridine (A), quinoline (B), 2-picoline (C), 2-fluoropyridine (D), and 8-fluoroquinoline (E). Ligand 2AA, for example, has a 1,3-diethynylbenzene core (2) and two pyridyl donors (A).
All ligands used in this work were synthesised using standard techniques and characterised by NMR spectroscopy and high resolution mass spectrometry (HR-MS). Details can be found in the SI.
All the cages in this work are tetracationic and prepared as the BF4− salts. For clarity, however, the charge and counterions are generally omitted from the main text. For example, [Pd21AA22AA2](BF4)4 may be written as Pd21AA22AA2. Formation of the heteroleptic cages was confirmed by NMR spectroscopy, 1H DOSY and electrospray ionisation (ESI) MS. Details can be found in the SI.
Quinoline donor on diverging ligand
Ligand 1AB incorporates two different donors: an unsubstituted pyridine (A), and a bulkier quinoline (B). We previously reported the self-assembly of heteroleptic cage Pd21AB22AA2 (Fig. 3a) in CD3CN that formed predominantly as the intuitively more sterically encumbered syn-isomer.18 This result is contrary to chemical intuition and molecular modelling (GFN2-xTB/MeCN20 calculated in Orca21) of the cationic cage architecture alone (Fig. 2) which does not consider intermolecular interactions. This indicated that interactions beyond the primary structure of the cage were influencing isomer selectivity.
 |
| Fig. 3 Partial 1H NMR spectra (400 MHz, CD3CN, 298 K), with major syn-isomer peaks labelled, of (a) [Pd21AB22AA2](BF4)4, (b) [Pd21AB23AA2](BF4)4, and (c) [Pd21AB24AA2](BF4)4. (d) Partial NOESY spectrum (600 MHz, CD3CN, 298 K) of [Pd21AB22AA2](BF4)4 with key peaks used to identify the syn- (s) and anti-isomers (a). | |
To explore the generality of this design, the self-assembly of 1AB with alternative symmetric ligands 3AA and 4AA (featuring pyridyl and tolyl core units, respectively) was investigated. To this end, 1AB and 3AA/4AA were combined in a 1
:
1 ratio with [Pd(CH3CN)4](BF4)2 (used as the source of Pd(II) throughout this work) in MeCN and equilibrated at 70 °C for 24 h. Formation of the desired [Pd2123/42]4+ cage structures was confirmed by ESI-MS, and the existence of both syn- and anti-isomers demonstrated by NMR spectroscopy (Fig. 3b and c).
The syn- and anti-isomers of these cages could be readily distinguished by NOESY (e.g. Fig. 3d); interactions between protons from the two ends of 1AB (e.g. HB⋯HI) would only be expected from the antiparallel arrangement present in the anti-isomer (and were only observed for the minor species in each instance).
Both Pd21AB23AA2 and Pd21AB24AA2 formed the syn-isomer as the major product in similar amounts to the previously reported Pd21AB22AA2 (77 ± 5%; Fig. S292). The identity of the core unit in ligand 2/3/4 was therefore shown not to materially affect isomer selectivity.
Picoline donor on diverging ligand
Ligand 1AC features a 2-picolyl donor (C) in combination with an unsubstituted pyridine (A). In contrast to 1AB, 1AC does not possess acidic exohedral protons adjacent to the coordinating atoms of the bulky donor. Based on this, it was predicted that the heteroleptic cages with 2AA, 3AA and 4AA would all form predominantly as the anti-isomers to avoid steric clash between the picolyl units. It was somewhat surprising, therefore, that all three of the cages also formed the syn-isomers as the major products (∼66 ± 5%; Fig. S293) in CD3CN (Fig. 4a and b).
 |
| Fig. 4 (a) Partial 1H NMR spectrum (600 MHz, CD3CN, 298 K), with major syn-isomer peaks labelled, of [Pd21AC22AA2](BF4)4. (b) Partial NOESY spectrum (600 MHz, CD3CN, 298 K) of [Pd21AC22AA2](BF4)4 with key peaks used to identify the syn- (s) and anti-isomers (a). (c) Visualisation of the coordination sphere sites of anti- and syn-Pd21AC22AA2 cage isomers from geometry-optimised models (GFN2-xTB). (d) SCXRD structures of syn-[Pd21AC23AA2]4+, showing endohedral BF4− counterion and exohedral CH3CN solvent molecule interacting with the cage, and anti-[Pd21AC24AA2]4+. | |
This selectivity was rationalised by comparing the coordination environments of the syn- and anti-isomers (Fig. 4c). A single picolyl unit on both faces of the anti-isomers is sufficient to significantly block interactions with both external coordination spheres of the cages. In contrast, the syn-isomers provide two different coordination spheres: one with two picolyl units, and a second, unencumbered, tetrapyridyl environment. The latter provides a single site with acidic protons HB and Hb′ that could engage in HB interactions to stabilise the otherwise unfavourable accumulation of steric bulk at the other end of the cage. This idea was supported by single crystal X-ray diffraction (SCXRD) studies (see below). As such, intermolecular non-covalent interactions on just one face of the cages are sufficient to overcome intramolecular steric interactions.
It is noted that Pd21AC24AA2 did not form exclusively as the heteroleptic assemblies. This was most likely the result of partial occlusion of the cavity by the tolyl methyl group, inhibiting access for anions/solvents necessary as templates.
The solid-state structures of Pd21AC23AA2 and Pd21AC24AA2 were determined by SCXRD (Fig. 4d). Intriguingly, Pd21AC24AA2 crystallised as the minor anti-isomer; this is presumably simply a facet of solid-state packing interactions. The structure of syn-Pd21AC23AA2 revealed an acetonitrile molecule engaging in quadfurcated hydrogen bond interactions with the tetrapyridyl face of the cage (C–H⋯N 2.62–2.72 Å), supporting the idea that such interactions could stabilise the syn-isomers in solution.22
Alternative donor combinations on diverging ligand
To see how modifications to the donor units affected isomer selectivity, four variants of 1AB were prepared (Fig. 5). 1BC and 1BD possess quinoline donors (B) combined with 2-picoline (C) or 2-fluoropyridine (D), respectively, whilst an 8-fluoroquinoline (E) donor was incorporated with an unsubstituted pyridine (A) into ligand 1AE. In each of these ligands, compared to 1AB, acidic protons on either the pyridine (1BC and 1BD) or quinoline (1AE) were replaced with moieties that could not act as HB donors. Finally, 1CE, with both picoline and 8-fluoroquinoline donors, was also synthesised.
 |
| Fig. 5 Summary of the observed syn/anti ratios in CD3CN for combinations of low-symmetry ligands 1, with various donor combinations, and symmetrical ligand 2AA. | |
In the case of Pd21BC22AA2, a 1
:
1 mixture of the syn- and anti-isomers formed (Fig. S294), demonstrating a loss of selectivity. Computational modelling revealed an insignificant (∼1 kJ mol−1) energy difference between the two isomers. As such, it can be concluded that the sum of interaction energies in the first and second coordination spheres for each isomer are virtually identical.
Both Pd21BD22AA2 and Pd21AE22AA2 (Fig. 6a and b) formed predominantly (∼70% each) as the anti-isomers (confirmed by NOESY analysis, e.g. Fig. 6c). As the substitution of hydrogen atoms for fluorine is widely regarded to have minimal impact on steric bulk,23 additional steric hindrance beyond that of Pd21AB22AA2 would not seem to be a major factor in the observed inversion of isomer selectivity. The loss of acidic protons capable of forming HB interactions, combined with electrostatic repulsion between fluorine atoms, seem more likely to be the major driving forces in promoting formation of the anti-isomer with these systems. As such, Pd21CE22AA2, with no acidic exohedral protons on ligand 1, was expected to form almost exclusively as the anti-isomer. Although this was indeed the major product (∼76%), the formation of significant amounts of the syn-isomer suggested that it was still possible to achieve substantive non-covalent interactions in the second coordination spheres of the syn-isomer.
 |
| Fig. 6 Partial 1H NMR spectra (600 MHz, CD3CN, 298 K) of (a) [Pd21BD22AA2](BF4)4 and (b) [Pd21AE22AA2](BF4)4 with major anti-isomer peaks labelled; partial NOESY spectrum (600 MHz, CD3CN, 298 K) of [Pd21AE22AA2](BF4)4 with key peaks used to identify the major anti-isomer; (d) partial 1H NMR spectrum (400 MHz, CD3CN, 298 K) of [Pd21CE22AA2](BF4)4 with major anti-isomer peaks labelled; (e) geometry-optimised models (GFN2-xTB) of the major anti-isomers of these cages. | |
The combinations of donor heterocycles investigated demonstrated varying isomer ratios could be achieved (24 to 77% syn). The energy-raising steric interactions between quinoline and picoline units in 1AB and 1AC in syn-Pd2122AA2 could be offset by stabilising non-covalent interactions with the cages, whilst repulsive interactions between fluorinated heterocycles in 1BD and 1AE were sufficient to promote formation of anti-isomers. Indeed, inversion of the isomer selectivity between favouring anti and syn could be achieved through simply replacing a proton with a fluorine (1AE and 1BD vs. 1AB), demonstrating the potential for minor structural modifications to be used to drastically alter self-assembly profiles.
Bulky donors on converging ligand
Having observed preferential formation of the syn-isomers of Pd21AB22AA2 and Pd21AC22AA2, it was sought to determine whether there would be any impact on isomer selectivity from locating the bulky donors on the converging ligand, 2, instead of the diverging ligand. To this end, the heteroleptic cages assembled from 1AA and unsymmetric 2AB/2AC (Fig. 7a) were examined.
 |
| Fig. 7 (a) Structure of ligands 1AA, 2AB and 2AC. Partial 1H NMR spectra (600 MHz, CD3CN, 298 K), with major anti-isomer peaks labelled, of (b) [Pd21AA22AB2]4+ and (c) [Pd21AA22AC2]4+. (d) Structures of anti-isomers of P-[Pd21AA22AB2]4+ (SCXRD) and M-[Pd21AA22AC2]4+ (GFN2-xTB geometry-optimised model). | |
In contrast to the previously studied systems with 1AB and 1AC, NMR analysis (in CD3CN; Fig. 7b and c) of the Pd21AA22AB/2AC2 cages showed the anti-isomers to be the major species for both (∼73% (Fig. S298) and ∼70% (Fig. S299) with 2AB and 2AC, respectively). The solid-state structure of anti-[Pd21AA22AB2](BF4)4 was also determined by SCXRD (Fig. 7d; the cage crystallised as a racemic mixture of the P and M enantiomers).24 This subtle design change was thus sufficient to shift the balance between coordination sphere interactions driving the isomer selectivity. Geometry-optimised models of the syn- and anti-isomers of cis-[Pd21AA22AB/2AC2]4+ suggested the former were more sterically crowded compared to the cis-[Pd21AB/1AC22AA2]4+ systems, manifested as an increase in relative computed energy compared to the anti-isomers (ΔE = 18.3 and 16.1 kJ mol−1 for the 2AB and 2AC cages, respectively). Thus, by slightly increasing the steric hindrance between bulky donors in the syn-isomers, simply through changing their location within the cages, this became the major driving force in isomer selectivity.
Cages assembled from two low-symmetry ligands
Finally, the self-assembly of four possible cages from pairs of low-symmetry ligands, namely 1AB, 1AC, 2AB and 2AC, were investigated (Fig. 8a). For such cis-Pd2LA2LB2 systems there are six possible isomers (excluding enantiomers, I–VI; Fig. 8) depending upon the relative orientation of the two different low-symmetry ligands. Based on previous results it was anticipated that isomer VI would inherently be the lowest energy isomer based on steric arguments due to the trans arrangement of bulky donor units. This was supported by molecular modelling (GFN2-xTB) that showed VI to be the lowest energy isomer by at least 13 kJ mol−1 for all four ligand combinations (Table S8–S11). Selective formation of this isomer would suggest minimising steric hindrance was the primary driving force dictating relative ligand orientation, whilst formation of other isomers would indicate alternative interactions were prominent.
 |
| Fig. 8 (a) The selective formation of particular isomers of Pd2LA2LB2-type cages (GXN2-xTB geometry-optimised models shown) from combinations of ligands 1AB/1AC and 2AB/2AC was observed. Partial 1H NMR spectra (600 MHz, 298 K) of (b) [Pd21AB22AB2](BF4)4 (d6-DMSO) with peaks assigned to major isomer V labelled (# = minor isomer; * = [Pd22AB4]4+); and (c) [Pd21AC22AC2](BF4)4, (d) [Pd21AB22AC2](BF4)4, and (e) [Pd21AC22AB2](BF4)4 (all CD3CN) with peaks assigned to major product, isomer VI, labelled. | |
For the combination of 1AB and 2AB an ill-defined mixture formed in CD3CN that defied analysis. Repeating the self-assembly in d6-DMSO resulted in more tractable NMR data (Fig. 8b). Signals in the 1H NMR spectrum could be readily identified for the homoleptic assembly of 2AB (∼30% yield). Two additional sets of signals, however, belonged to Pd21AB22AB2 cage isomers (the formation of which was confirmed by ESI-MS) forming approximately 35% and 13% of the mixture. NOESY allowed assignment of the major cage isomer as V. As such, preferential formation of a cis arrangement of quinoline donors was observed, suggesting that interactions in the second coordination sphere were the major drivers of isomer selectivity for this system.
A single major species was observed to form in ∼62% yield (Fig. S301) from the equilibrated 1
:
1
:
1 mixture of 1AC, 2AC and [Pd(CH3CN)4](BF4)2 in CD3CN (Fig. 8c). ESI-MS confirmed the anticipated formulation of the assembled heteroleptic structure. NOE coupling (Fig. 9) of both methyl groups (HG of 1AC and Hk of 2AC) with both external ortho pyridyl protons (HB of 1AC and Hb of 2AC) was consistent with only two possible isomers, with the picolyl units arranged either cis (III) or trans (VI) to each other. NOE coupling (Fig. 9 inset) exclusively between internal protons HA and Hl and between HH and Ha (and not HA⋯Ha or HH⋯Hl) and the lack of coupling between Hb and HB, however, confirmed that the major product formed was isomer VI. Thus, alleviation of steric hindrance appeared to be the primary driving force in isomer selectivity.
 |
| Fig. 9 Partial NOESY spectrum (600 MHz, CD3CN, 298 K) of [Pd21AC22AC2](BF4)4 identifying the major product as isomer VI. | |
Similarly, both Pd21AB22AC2 and Pd21AC22AB2 (Fig. 8d and e, respectively) formed isomer VI as the major species (each ∼45% yield; Fig. S302 and S303), with pairs of quinoline and picoline donors arranged trans to each other on opposite faces of the cage. Again, this suggested minimising steric interactions was the major driving force at play.
These results are consistent with the earlier systems examined. For alternative isomers than VI to be formed, suitable sites for non-covalent interactions would need to be accessible. This is possible with isomer I, but having all four bulky heterocycles on one face raises the system energy too much (ΔE >40 kJ mol−1 relative to VI). Isomers that provide a syn orientation of 2AB or 2AC (II and V) were previously shown to be relatively unfavourable, while isomers III and IV would place picoline and quinoline units adjacent to each other, inhibiting access to the acidic quinolyl protons. Thus, the preferential formation of isomer VI can be rationalised based on the principles established in this work.
Conclusions
We have investigated the self-assembly of heteroleptic Pd2LA2LB2-type coordination cages from low-symmetry ligands incorporating different combinations of heterocyclic donors. Integrative self-assembly of the two ligands is directed by geometric complementarity, while the relative orientation of the low-symmetry scaffolds (i.e. isomer selectivity) is driven by coordination sphere interactions. Isomer selectivity could be changed by relatively subtle structural variations, including exchanging a proton for a fluorine atom, or changing the relative locations of heterocycles within the cage structures.
In the case of cages assembled with one low-symmetry ligand, this allowed formation of cages primarily as the syn-isomer (up to ∼77%), primarily as the anti-isomer (up to ∼76%), or an approximately equal mixture of the two. Selective formation of particular isomers of heteroleptic cages assembled from two low-symmetry ligands (up to ∼62%) was also demonstrated, the assembly of which could be rationally explained from the underlying design principles delineated from this work. As such, we have shown how ligand design can be used to promote interactions in the first or second coordination spheres as the major drivers of isomer selectivity.
Through the combined computational and experimental investigations of the systems explored, it has been possible to gain insight into how structural designs can modulate the relative impact of both intramolecular (first coordination sphere) and intermolecular (second coordination sphere) interactions in directing self-assembly outcomes. In the continued pursuit of developing ever more structurally sophisticated metallo-supramolecular assemblies, understanding (i) how different directing strategies can be used in a synergistic manner, and (ii) the effects of environment (e.g. solvent) on thermodynamic self-assembly processes, will enable the design of increasingly structurally and functionally advanced, precision-engineered systems capable of exhibiting bespoke and nuanced properties and behaviours.
Author contributions
PM carried out the synthesis, characterisation and data analysis. PM and LM collected and analysed the SCXRD data. JEML conceived and directed the project, secured funding, performed molecular modelling, aided data analysis and wrote the manuscript. All authors contributed to editing and approved the final manuscript.
Conflicts of interest
There are no conflicts to declare.
Data availability
CCDC 2390755 ([Pd21AA22AB2](BF4)4), 2390756 ([Pd21AC24AA2](BF4)4) and 2390758 ([Pd21AC23AA2](BF4)4) contain the supplementary crystallographic data for this paper.25a–c
The data supporting this article have been included as part of the SI. See DOI: https://doi.org/10.1039/d5sc04881h.
Acknowledgements
We thank Dr Cécile Le Duff for assistance with the collection of NMR data, Dr Christopher Williams for the collection of MS data, and HWB-NMR staff at the University of Birmingham for providing open access to their NMR spectrometers. Dr Dan Preston (ANU) is thanked for useful discussions and optimism. This work was supported by the Royal Society (URF\R1\221740 and RF\ERE\221016) and the University of Birmingham (including a PhD studentship to PM). JEML is a Royal Society University Research Fellow.
References
-
(a) A. Schmidt, A. Casini and F. E. Kühn, Coord. Chem. Rev., 2014, 275, 19 CrossRef CAS;
(b) T. R. Cook and P. J. Stang, Chem. Rev., 2015, 115, 7001 CrossRef CAS;
(c) M. D. Ward, C. A. Hunter and N. H. Williams, Acc. Chem. Res., 2018, 51, 2073 CrossRef CAS PubMed;
(d) D. Zhang, T. K. Ronson and J. R. Nitschke, Acc. Chem. Res., 2018, 51, 2423 CrossRef CAS PubMed;
(e) B. S. Pilgrim and N. R. Champness, ChemPlusChem, 2020, 85, 1842 CrossRef CAS PubMed;
(f) S. Lee, H. Jeong, D. Nam, M. S. Lah and W. Choe, Chem. Soc. Rev., 2021, 50, 528 RSC;
(g) J. E. M. Lewis, Chem. Commun., 2022, 58, 13873 RSC;
(h) T. Teteishi, M. Yoshimura, S. Tokuda, F. Matsuda, D. Fujita and S. Furukawa, Coord. Chem. Rev., 2022, 467, 214612 CrossRef;
(i) A. J. McConnell, Chem. Soc. Rev., 2022, 51, 2957 RSC;
(j) R. Banerjee, D. Chakraborty and P. S. Mukherjee, J. Am. Chem. Soc., 2023, 145, 7692 CrossRef CAS;
(k) S. Sharma, M. Sarkar and D. K. Chand, Chem. Commun., 2023, 59, 535 RSC;
(l) C. J. T. Cox, J. Hale, P. Molinska and J. E. M. Lewis, Chem. Soc. Rev., 2024, 53, 10380 RSC.
-
(a) R. Custelcean, Chem. Soc. Rev., 2014, 43, 1823 RSC;
(b) D. Preston, K. M. Patil, A. T. O'Neil, R. A. S. Vasdev, J. A. Kitchen and P. E. Kruger, Inorg. Chem. Front., 2020, 7, 2990 RSC;
(c) B. J. J. Timmer and T. J. Mooibroek, Chem. Commun., 2021, 57, 7184 RSC;
(d) S. J. Allison, J. Bryk, C. J. Clemett, R. A. Faulkner, M. Gingner, H. B. S. Griffiths, J. Harmer, P. J. Owen-Lynch, E. Pinder, H. Wurdak, R. M. Phillips and C. R. Rice, Nat. Commun., 2021, 12, 3898 CrossRef CAS;
(e) V. Sivalingam, S. Krishnaswamy and D. K. Chand, Chem.–Eur. J., 2023, 29, e202300891 CrossRef CAS;
(f) S. Sudan, D. W. Chen, C. Berton, F. Fadaei-Tirani and K. Severin, Angew. Chem., Int. Ed., 2023, 62, e202218072 CrossRef CAS PubMed;
(g) W.-L. Jiang, B. Huang, X.-L. Zhao, X. Shi and H.-B. Yang, Chem, 2023, 9, 2655 CrossRef CAS;
(h) Y.-L. Lai, m. Xie, X.-C. Zhou, X.-Z. Wang, X.-W. Zhu, D. Luo, X.-P. Zhou and D. Li, Angew. Chem., Int. Ed., 2024, 63, e202402829 CrossRef CAS PubMed;
(i) J. I. Virtue, S. Tsoukatos, M. R. Johnston and W. M. Bloch, Chem. Sci., 2024, 15, 19119 RSC.
-
(a) E. G. Percástegui, Chem. Commun., 2022, 58, 5055 RSC;
(b) I. A. Riddell, M. M. J. Smulders, J. K. Clegg and J. R. Nitschke, Chem. Commun., 2011, 47, 457 RSC;
(c) C. G. P. Taylor, J. R. Piper and M. D. Ward, Chem. Commun., 2016, 52, 6225 RSC;
(d) S. Ganta and D. K. Chand, Inorg. Chem., 2018, 57, 3634 CrossRef CAS;
(e) A. Platzek, S. Juber, C. Yurtseven, S. Hasegawa, L. Schneider, C. Drechsler, K. E. Ebbert, R. Rudolf, Q.-Q. Yan, J. J. Holstein, L. V. Schäfer and G. H. Clever, Angew. Chem., Int. Ed., 2022, 61, e202209305 CrossRef CAS PubMed;
(f) T. K. Ronson, J. P. Carpenter and J. R. Nitschke, Chem, 2022, 8, 557 CrossRef CAS.
-
(a) J. E. M. Lewis, E. L. Gavey, S. A. Cameron and J. D. Crowley, Chem. Sci., 2012, 3, 778 RSC;
(b) Y.-R. Zheng, K. Suntharalingam, T. C. Johnstone and S. L. Lippard, Chem. Sci., 2015, 6, 1189 RSC;
(c) A. Schmidt, V. Molano, M. Hollering, A. Pöthig, A. Casini and F. E. Kühn, Chem.–Eur. J., 2016, 22, 2253 CrossRef CAS PubMed;
(d) Y. Fang, X. Lian, Y. Huang, G. Fu, Z. Xiao, Q. Wang, B. Nan, J.-P. Pellois and H.-C. Zhou, Small, 2018, 14, 1802709 CrossRef;
(e) F. J. Rizzuto, J. P. Carpenter and J. R. Nitschke, J. Am. Chem. Soc., 2019, 141, 9087 CrossRef CAS PubMed;
(f) G. Li, T. K. Ronson, R. Lavendomme, Z. Huang, C. Fuertes-Espinosa, D. Zhang and J. R. Nitschke, Chem, 2023, 9, 1549 CrossRef CAS;
(g) Y.-H. Huang, Y.-L. Lu, Z.-M. Cao, X.-D. Zhang, C.-H. Liu, H.-S. Xu and C.-Y. Su, J. Am. Chem. Soc., 2024, 146, 21677 CrossRef;
(h) G. Montà-González, D. Bastante-Rodríguez, A. García-Fernández, P. J. Lusby, R. Martínez-Máñez and V. Martí-Centelles, Chem. Sci., 2024, 15, 10010 RSC.
-
(a) A. J. Gosselin, C. A. Rowland and E. D. Bloch, Chem. Rev., 2020, 120, 8987 CrossRef CAS PubMed;
(b) Q.-W. Zeng, L. Hu, Y. Niu, D. Wang, Y. Kang, H. Jia, W.-T. Dou and L. Xu, Chem. Commun., 2024, 60, 3469 RSC;
(c) J. Roukala, J. Zhu, C. Giri, K. Rissanen, P. Lantto and V.-V. Telkki, J. Am. Chem. Soc., 2015, 137, 2411 CrossRef;
(d) D. Preston, K. F. White, J. E. M. Lewis, R. A. S. Vasdev, B. F. Abrahams and J. D. Crowley, Chem.–Eur. J., 2017, 23, 10559 CrossRef CAS;
(e) J. S. Wright, A. J. Metherell, W. M. Cullen, J. R. Piper, R. Dawson and M. D. Ward, Chem. Commun., 2017, 53, 4398 RSC;
(f) C. A. Rowland, G. R. Lorzing, A. J. Gosselin, B. A. Trump, G. P. A. Yap, C. M. Brown and E. D. Bloch, J. Am. Chem. Soc., 2018, 140, 11153 CrossRef CAS PubMed;
(g) J.-L. Zhu, D. Zhang, T. K. Ronson, W. Wang, L. Xu, H.-B. Yang and J. R. Nitschke, Angew. Chem., Int. Ed., 2021, 60, 11789 CrossRef CAS PubMed.
-
(a) C. J. Brown, F. D. Toste, R. G. Bergman and K. N. Raymond, Chem. Rev., 2015, 115, 3012 CrossRef CAS PubMed;
(b) Y. Xue, X. Hang, J. Ding, B. Li, R. Zhu, H. Pang and Q. Xu, Coord. Chem. Rev., 2021, 430, 213656 CrossRef CAS;
(c) T. K. Piskorz, V. Martí-Centelles, R. L. Spicer, F. Duarte and P. J. Lusby, Chem. Sci., 2023, 14, 11300 RSC;
(d) M. Yoshizawa, M. Tamura and M. Fujita, Science, 2006, 312, 251 CrossRef CAS;
(e) M. D. Pluth, R. G. Bergman and K. N. Raymond, Science, 2007, 316, 85 CrossRef CAS;
(f) J. L. Bolliger, A. M. Belenguer and J. R. Nitschke, Angew. Chem., Int. Ed., 2013, 52, 7958 CrossRef CAS;
(g) X. Jing, C. He, Y. Yang and C. Duan, J. Am. Chem. Soc., 2015, 137, 3967 CrossRef CAS PubMed;
(h) V. Martí-Centelles, A. L. Lawrence and P. J. Lusby, J. Am. Chem. Soc., 2018, 140, 2862 CrossRef;
(i) W. Cullen, A. J. Metherell, A. B. Wragg, C. G. P. Taylor, N. H. Williams and M. D. Ward, J. Am. Chem. Soc., 2018, 140, 2821 CrossRef CAS;
(j) A. Paul, M. A. Shipman, D. Y. Onabule, S. Sproules and M. D. Symes, Chem. Sci., 2021, 12, 5082 RSC;
(k) S. M. Bierschenk, J. Y. Pan, N. S. Settineri, U. Warzok, R. G. Bergman, K. N. Raymond and F. D. Toste, J. Am. Chem. Soc., 2022, 144, 11425 CrossRef CAS;
(l) E. O. Bobylev, J. Ruijter, D. A. Poole III, S. Mathew, B. de Bruin and J. N. H. Reek, Angew. Chem., Int. Ed., 2023, 62, e202218162 CrossRef CAS;
(m) R. G. DiNardi, S. Rasheed, S. S. Capomolla, M. H. Chak, I. A. Middleton, L. K. Macreadie, J. P. Violi, W. A. Donald, P. J. Lusby and J. E. Beves, J. Am. Chem. Soc., 2024, 146, 21196 CrossRef.
-
(a) M. Yoshizawa, T. Kusukawa, M. Fujita and K. Yamaguchi, J. Am. Chem. Soc., 2000, 122, 6311 CrossRef CAS;
(b) P. Mal, B. Breiner, K. Rissanen and J. R. Nitschke, Science, 2009, 324, 1697 CrossRef CAS PubMed;
(c) M. Yamashina, Y. Sei, M. Akita and M. Yoshizawa, Nat. Commun., 2014, 5, 4662 CrossRef CAS PubMed;
(d) M. Canton, A. B. Grommet, L. Pesce, J. Gemen, S. Li, Y. Diskin-Posner, A. Credi, G. M. Pavan, J. Andréasson and R. Klajn, J. Am. Chem. Soc., 2020, 142, 14557 CrossRef CAS;
(e) S. Hasegawa, S. L. Meichsner, J. J. Holstein, A. Baksi, M. Kasanmascheff and G. H. Clever, J. Am. Chem. Soc., 2021, 143, 9718 CrossRef CAS;
(f) R. Sumida, Y. Tanaka, K. Niki, Y. Sei, S. Toyota and M. Yoshizwa, Chem. Sci., 2021, 12, 9946 RSC;
(g) M. Ray, S. Krishnaswamy, A. K. Pardhan and D. K. Chand, Chem. Mater., 2023, 35, 6702 CrossRef CAS;
(h) J. C. Dorrat, R. J. Young, C. G. P. Taylor, M. B. Tipping, A. J. Blok, D. R. Turner, A. I. McKay, S. Ovenden, M. D. Ward, G. H. Dennison and K. L. Tuck, Dalton Trans., 2023, 52, 11802 RSC.
-
(a) D. Zhang, T. K. Ronson, Y.-Q. Zou and J. R. Nitschke, Nat. Rev. Chem., 2021, 5, 168 CrossRef CAS PubMed;
(b) C. Zhu, H. Tang, K. Yang, Y. Fang, K.-Y. Wawng, Z. Xiao, X. Wu, Y. Li, J. A. Powell and H.-C. Zhou, J. Am. Chem. Soc., 2021, 143, 12560 CrossRef CAS;
(c) P.-F. Cui, X.-R. Liu, Y.-J. Lin, Z.-H. Li and G.-X. Jin, J. Am. Chem. Soc., 2022, 144, 6558 CrossRef CAS PubMed;
(d) L.-J. Wang, S. Bai and Y.-F. Han, J. Am. Chem. Soc., 2022, 144, 16191 CrossRef CAS PubMed;
(e) D. Chakraborty, R. Saha, J. K. Clegg and P. S. Mukherjee, Chem. Sci., 2022, 13, 11764 RSC;
(f) C.-W. Zhou, X.-Z. Wang, M. Xie, R.-Q. Xia, D. Luo, Z.-X. Lian, G.-H. Ning, W. Lu, X.-P. Zhou and D. Li, Angew. Chem., Int. Ed., 2023, 62, e202315020 CrossRef CAS;
(g) A. Ghosh, J. Pruchyathamkorn, C. F. Espinosa and J. R. Nitschke, J. Am. Chem. Soc., 2024, 146, 2568 CrossRef CAS.
-
(a) S. Pullen, J. Tessarolo and G. H. Clever, Chem. Sci., 2021, 12, 7269 RSC;
(b) C. T. McTernan, J. A. Davies and J. R. Nitschke, Chem. Rev., 2022, 122, 10393 CrossRef CAS;
(c) J. E. M. Lewis, Trends Chem., 2023, 5, 717 CrossRef;
(d) Z. T. Avery, J. L. Algar and D. Preston, Trends Chem., 2024, 6, 352 CrossRef.
-
(a) W. M. Bloch and G. H. Clever, Chem. Commun., 2017, 53, 8506 RSC;
(b) D. Bardhan and D. K. Chand, Chem.–Eur. J., 2019, 25, 12241 CrossRef CAS PubMed.
-
(a) J. E. M. Lewis and J. D. Crowley, ChemPlusChem, 2020, 85, 815 CrossRef CAS;
(b) D. Tripathy, N. B. Debata, K. C. Naik and H. S. Sahoo, Coord. Chem. Rev., 2022, 456, 214396 CrossRef CAS.
-
(a) D. Preston and J. D. Evans, Angew. Chem., Int. Ed., 2023, 62, e202314378 CrossRef CAS;
(b) M. Parbin, V. Sivalingam and D. K. Chand, Angew. Chem., Int. Ed., 2024, 63, e202410219 CrossRef CAS PubMed;
(c) A. Kumar, S. Krishnaswamy and D. K. Chand, Angew. Chem., Int. Ed., 2025, 64, e202416332 CrossRef CAS;
(d) M. R. Black, S. Bhattacharyya, S. P. Argent and B. S. Pilgrim, J. Am. Chem. Soc., 2024, 146, 28233 CAS;
(e) S. Sharma, D. John and D. K. Chand, Chem.–Asian J., 2025, 20, e202401941 CrossRef CAS PubMed;
(f) H. Yu, Z. Guo, J. Tang, N. Han, J. Shi, M. Li, H. Zhang and M. Wang, Chem. Sci., 2025, 16, 6114 RSC.
-
(a) J.-R. Li and H.-C. Zhou, Nat. Chem., 2010, 2, 893 CrossRef CAS;
(b) Q.-F. Sun, S. Sato and M. Fujita, Angew. Chem., Int. Ed., 2014, 53, 13510 CrossRef CAS PubMed;
(c) W. M. Bloch, Y. Abe, J. J. Holstein, C. M. Wandtke, B. Dittrich and G. H. Clever, J. Am. Chem. Soc., 2016, 138, 13750 CrossRef CAS PubMed;
(d) W. M. Bloch, J. J. Holstein, W. Hiller and G. H. Clever, Angew. Chem., Int. Ed., 2017, 56, 8285 CrossRef CAS;
(e) J. A. Findlay, K. M. Patil, M. G. Gardiner, H. I. MacDermott-Opeskin, M. L. O'Mara, P. E. Kruger and D. Preston, Chem.–Asian J., 2022, 17, e202200093 CrossRef CAS PubMed;
(f) K. Wu, J. Tessarolo, A. Baksi and G. H. Clever, Angew. Chem., Int. Ed., 2022, 61, e202205727 Search PubMed;
(g) K. Wu, E. Benchimol, A. Baksi and G. H. Clever, Nat. Chem., 2024, 16, 584 CrossRef CAS.
-
(a) D. Ogata and J. Yuasa, Angew. Chem., Int. Ed., 2019, 58, 18424 CrossRef CAS;
(b) J. E. M. Lewis, A. Tarzia, A. J. P. White and K. E. Jelfs, Chem. Sci., 2020, 11, 677 RSC;
(c) S. S. Mishra, S. V. K. Kompella, S. Krishnaswamy, S. Balasubramanian and D. K. Chand, Inorg. Chem., 2020, 59, 12884 CrossRef CAS PubMed;
(d) J. E. M. Lewis, Chem.–Eur. J., 2021, 27, 44454 Search PubMed;
(e) R.-J. Li, A. Marcus, F. Fadaei-Tirani and K. Severin, Chem. Commun., 2021, 57, 10023 RSC;
(f) H. Yu, J. Li, C. Shan, T. Lu, X. Jiang, J. Shi, L. Wojtas, H. Zhang and M. Wang, Angew. Chem., Int. Ed., 2021, 60, 26523 CrossRef CAS;
(g) A. Tarzia, J. E. M. Lewis and K. E. Jelfs, Angew. Chem., Int. Ed., 2021, 60, 20879 CrossRef CAS;
(h) R.-J. Li, A. Tarzia, V. Posligua, K. E. Jelfs, N. Sanchez, A. Marcus, A. Baksi, G. H. Clever, F. Fadaei-Tirani and K. Severin, Chem. Sci., 2022, 13, 11912 RSC;
(i) J. de Montmollin, A. B. Solea, D. W. Chen, F. Fadaei-Tirani and K. Severin, Inorg. Chem., 2024, 63, 4583 CrossRef CAS PubMed;
(j) S. E. Walker, N. Kyratzis, D. U. Sawant, A. I. McKay, K. L. Tuck and D. R. Turner, Inorg. Chem., 2024, 63, 15659 CrossRef CAS PubMed;
(k) J. A. Gome, Z. T. Avery, N. R. Lawson, O. G. Stansfield, J. D. Evans, M. G. Gardiner, T. U. Connell and D. Preston, Angew. Chem., Int. Ed., 2025, 64, e202503473 CrossRef CAS.
- M. Yoshizawa, M. Nagao, K. Kumzawa and M. Fujita, J. Organomet. Chem., 2005, 690, 5383 CrossRef CAS.
-
(a) D. Preston, J. E. Barnsley, K. C. Gordon and J. D. Crowley, J. Am. Chem. Soc., 2016, 138, 10578 CrossRef CAS PubMed;
(b) R. Zhu, W. M. Bloch, J. J. Holstein, S. Mandal, L. V. Schäfer and G. H. Clever, Chem.–Eur. J., 2018, 24, 12734 CrossRef;
(c) R.-J. Li, J. Tessarolo, H. Lee and G. H. Clever, J. Am. Chem. Soc., 2021, 143, 3865 CrossRef CAS PubMed;
(d) B. Chen, J. J. Holstein, A. Platzek, L. Schneider, K. Wu and G. H. Clever, Chem. Sci., 2022, 13, 1829 RSC;
(e) Y. Liu, S.-H. Liao, W.-T. Dai, Q. Bai, S. Lu, H. Wang, X. Li, Z. Zhang, P. Wang, W. Lu and Q. Zhang, Angew. Chem., Int. Ed., 2023, 62, e202217215 CrossRef CAS;
(f) Z. Guo, H. Yu, J. Shi, N. Han, G. Wu, H. Zhang, B. Li and M. Wang, Angew. Chem., Int. Ed., 2025, 64, e202425369 CrossRef CAS;
(g) Y.-M. Tan, L.-M. Zhang, Q. Bai, Z. Zhang, P. Wang and Q. Zhang, Chem. Sci., 2025, 16, 4625 RSC.
-
(a) R. A. S. Vasdev, D. Preston, C. A. Casey-Stevens, V. Martí-Centelles, P. J. Lusby, A. L. Garden and J. D. Crowley, Inorg. Chem., 2023, 62, 1833 CrossRef CAS;
(b) B. E. Barber, E. M. G. Jamieson, L. E. M. White and C. T. McTernan, Chem, 2024, 10, 2792 CrossRef CAS.
- P. Molinska, A. Tarzia, L. Male, K. E. Jelfs and J. E. M. Lewis, Angew. Chem., Int. Ed., 2023, 62, e202315451 CrossRef CAS.
- R.-J. Li, J. de Montmollin, F. Fadaei-Tirani, R. Scopelliti and K. Severin, Dalton Trans., 2023, 52, 6451 RSC.
- C. Bannwarth, S. Ehlert and S. Grimme, J. Chem. Theory Comput., 2019, 153, 1652 CrossRef PubMed.
-
(a) F. Neese, Wiley Interdiscip. Rev.: Comput. Mol. Sci., 2012, 2, 73 CAS;
(b) F. Neese, Wiley Interdiscip. Rev.: Comput. Mol. Sci., 2018, 8, e1327 Search PubMed.
- The effects of different solvents on isomer distributions for Pd21AB22AA2 and Pd21AC22AA2, and differences in interactions of −OTs anions with the syn- and anti-isomers, are described in the SI Section S4.
- D. O'Hagan, Chem. Soc. Rev., 2008, 37, 308 RSC.
- M. C. Biagini, M. Ferrari, M. Lanfranchi, L. Marchió and M. A. Pellinghelli, J. Chem. Soc., Dalton Trans., 1999, 1575 RSC.
-
(a) P. Molinska, L. Male and J. E. M. Lewis, CCDC [2390755]: Experimental Crystal Structure Determination, 2025, DOI:10.5517/ccdc.csd.cc2l7s4s;
(b) P. Molinska, L. Male and J. E. M. Lewis, CCDC [2390756]: Experimental Crystal Structure Determination, 2025, DOI:10.5517/ccdc.csd.cc2l7s5t;
(c) P. Molinska, L. Male and J. E. M. Lewis, CCDC [2390758]: Experimental Crystal Structure Determination, 2025, DOI:10.5517/ccdc.csd.cc2l7s7w.
|
This journal is © The Royal Society of Chemistry 2025 |
Click here to see how this site uses Cookies. View our privacy policy here.